Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Regen Innopharm Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so the pending work is divided across separate examination assignments.
LEE, JIA-HAI is the busiest examiner, with 1 pending matter. Because the busiest examiner handles only one matter, response strategy should remain application-specific rather than relying on a single portfolio-wide pattern.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285963 | CELL-PENETRATING PEPTIDE VARIANT AND USE THEREOF | LEE, JIA-HAI | — |
| 18272824 | COMPOSITION COMPRISING MIR 145 INHIBITOR AS ACTIVE INGREDIENT FOR TREATMENT OF MYOCARDIAL INFARCTION | HUDSON, AMY ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285963 | CELL-PENETRATING PEPTIDE VARIANT AND USE THEREOF | LEE, JIA-HAI | — |
| 18272824 | COMPOSITION COMPRISING MIR 145 INHIBITOR AS ACTIVE INGREDIENT FOR TREATMENT OF MYOCARDIAL INFARCTION | HUDSON, AMY ROSE | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285963 | CELL-PENETRATING PEPTIDE VARIANT AND USE THEREOF | LEE, JIA-HAI | 1658 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18272824 | COMPOSITION COMPRISING MIR 145 INHIBITOR AS ACTIVE INGREDIENT FOR TREATMENT OF MYOCARDIAL INFARCTION | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Jul 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegen Innopharm Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jia-Hai Lee has the most, with 1 of Regen Innopharm Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
